GMMG phase III trial ReLApsE Salvage autologous transplant and lenalidomide maintenance vs. len-Dex

Time Frame: 2010 and 2016

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Eudra CT-No: 2009-013856-61.

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

German-speaking myeloma multicenter group (GMMG)

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Leukemia; 2021

Click here for details

GMMG - The German Speaking Myeloma Multicenter Group

---

731. CLINICAL AUTOLOGOUS TRANSPLANTATION: RESULTS: MULTIPLE MYELOMA: SALVAGE AUTOLOGOUS TRANSPLANTS, MINIMAL RESIDUAL DISEASE, AND CHECKPOINT INHIBITORS| NOVEMBER 29, 2018

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Click here for details